<dpciv class="vapku"></dpciv>
  • 德晋贵宾厅

    B-hCTLA4/hOX40 mice

    C57BL/6-Ctla4tm1(CTLA4)Bcgen Tnfrsf4tm1(TNFRSF4)Bcgen/Bcgen • 120531

    B-hCTLA4/hOX40 mice

    Product nameB-hCTLA4/hOX40 mice
    Catalog number120531
    Strain nameC57BL/6-Ctla4tm1(CTLA4)Bcgen Tnfrsf4tm1(TNFRSF4)Bcgen/Bcgen
    Strain backgroundC57BL/6
    NCBI gene ID7293,1493 (Human)
    AliasesOX40; ACT35; CD134; IMD16; TXGP1L; CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3

    在此页面上

    • Description
    • Targeting strategy
    • Phenotypic analysis
    • Efficacy

    海报

    查看全部

      发表文章

        Description

        Live
         

        Targeting strategy

        Gene targeting strategy for B-hCTLA4/hOX40 mice. The exon 2 of the mouse Ctla4 gene that encodes the extracellular domain was replaced by human CTLA4 exon 3, and the exons 1-5 of the mouse Ox40 gene that encode the extracellular domain were replaced by human OX40 exons 1-5 in B-hCTLA4/hOX40 mice.

        Protein expression analysis

        Strain specific CTLA4 and OX40 expression analysis in homozygous B-hCTLA4/hOX40 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hCTLA4/hOX40 (H/H) mice stimulated with anti-CD3ε in vivo (7.5 μg/mice), and analyzed by flow cytometry with species-specific anti-CTLA4 antibody. Mouse CTLA4 and OX40 were exclusively detected in WT mice. Human CTLA4 CTLA4 and OX40 were exclusively detected in homozygous B-hCTLA4/hOX40 but not WT mice.

        Combination therapy of CTLA4 mAb (ipilimumab) and OX40 mAb

        Antitumor activity of anti-hOX40 antibody combined with anti-hCTLA4 antibody ipilimumab in B-hCTLA4/hOX40 mice. (A) Anti-hOX40 antibody combined with anti-hCTLA4 antibodies ipilimumab inhibited MC38 tumor growth in B-hCTLA4/hOX40 mice. Murine colon cancer MC38 cells (5×105) were subcutaneously implanted into homozygous B-hCTLA4/hOX40 mice (female, 5-8 week-old, n=8). Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with anti-hOX40 antibody combined with anti- hCTLA4 antibody ipilimumab with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of anti-hOX40 and anti-hCTLA4 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hCTLA4/hOX40 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hOX40 antibodies and h B-hCTLA4 antibodies. Values are expressed as mean ± SEM.

        * When publishing results obtained using this animal model, please acknowledge the source as follows: The animal model [B-hCTLA4/hOX40 mice] (Cat# 120531) was purchased from Biocytogen.